Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2020-08-20
Target enrollment:
Participant gender:
Summary
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that
have spread from the primary site (place where it started) to other places in the body.
Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.